Stock Financial Ratios

DEPO / DepoMed, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)384.28
Enterprise Value ($M)241.68
Book Value ($M)250.79
Book Value / Share4.09
Price / Book1.93
NCAV ($M)998.10
NCAV / Share16.28
Price / NCAV0.49
Income Statement (mra) ($M)
Net Income-88.72
Balance Sheet (mrq) ($M)
Cash & Equivalents107.58
Cash / Share1.76
Quick Ratio1.29
Current Ratio1.35
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.35
Return on Assets (ROA)-0.07
Return on Equity (ROE)-0.35
Identifiers and Descriptors
Central Index Key (CIK)1005201
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)63.01
Scoring Models
Piotroski F Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Current Per Share3.58
Minority Interest Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Assets Per Share17.28
Liabilities Current Per Share4.29
Retained Earnings Per Share-3.04
Additional Paid In Capital Per Share1.24
Property Plant And Equipment Net Per Share0.23
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Cash And Equivalents Per Share1.76
Inventory Per Share0.17
Inventory Finished Goods Per Share0.14
Accounts Receivable Per Share1.26
Inventory Work In Progress Per Share0.00
Liabilities And Stock Equity Per Share17.28
Long Term Debt Per Share0.00
Equity Per Share3.24
Assets Other Non Current Per Share0.02
Treasury Stock Per Share0.00
Inventory Raw Materials Per Share0.03
Debt Per Share0.00
Cash Per Share1.76
Liabilities Per Share14.04
Liabilities Other Non Current Per Share0.28
Property Plant And Equipment Per Share0.23
Intangibles Per Share13.46
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00

Related News Stories

Depomed Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-08 seekingalpha
The following slide deck was published by Depomed Inc. in conjunction with their 2017 Q3 earnings call. (8-2)

Depomed's (DEPO) CEO Arthur Higgins on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good afternoon and welcome to the Depomed's Third Quarter Fiscal Year 2017 Financial Results Conference Call. Please note that this event is being recorded. (8-3)

Your Daily Pharma Scoop: Portola's PDUFA, PDLI Makes Some Money, GWPH Completes Rolling NDA

2017-10-31 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (765-3)

Opioid Industry Faces Pressure From Investors With $1.3 Trillion - Bloomberg

2017-10-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (109-1)

DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses In Excess of $500,000 to Contact the Firm

2017-10-17 accesswire
LOS ANGELES, CA / ACCESSWIRE / October 17, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Depomed, Inc. ("Depomed" or the "Company") (NASDAQ: DEPO) for possible violations of federal securities laws from February 26, 2015 through August 7, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired Depomed shares during the Class Period, should contact the firm by October 17, 2017, the lead plaintiff motion deadline. (8-0)

CUSIP: 249908104